- Open Access
Therapeutic effects of human gingiva-derived mesenchymal stromal cells on murine contact hypersensitivity via prostaglandin E2–EP3 signaling
© The Author(s). 2016
Received: 8 January 2016
Accepted: 4 July 2016
Published: 2 August 2016
The immunomodulatory and anti-inflammatory functions of human gingiva-derived mesenchymal stromal cells (GMSCs) have been demonstrated in contact hypersensitivity (CHS) models; however, their therapeutic effect during the late phase of CHS has been poor.
The murine CHS model was induced by applying oxazolone to the ears of mice. Mesenchymal stromal cells were applied via two methods (intravenous or local injection) at three time points: 1 day before sensitization, 1 day before challenge, or 1 h after challenge. Prostaglandin E2 (PGE2) and sulprostone were administered subcutaneously 1 h after challenge.
The application of GMSCs, bone marrow mesenchymal stem cells, and adipose-derived stem cells all effectively suppressed CHS; however, GMSC treatment exhibited the greatest efficacy. Local injection of GMSCs led to a more marked attenuation of CHS compared with intravenous injection, especially during the late phase of CHS, and this manifested as decreased infiltration of inflammatory cells, suppression of the levels of various proinflammatory cytokines, reconstruction of the disrupted Th1/Th2 balance, and upregulation of regulatory T cells in the allergen contact areas. Pretreatment with indomethacin significantly abrogated the GMSC-mediated immunosuppressive effects, while PGE2 application reversed the effects of indomethacin pretreatment of GMSCs. Moreover, GMSC administration promoted the expression of EP3, a prostaglandin E receptor, and the application of sulprostone, an agonist of EP3, significantly attenuated CHS to a similar degree as that of GMSC administration.
GMSCs have reproducible and powerful immunomodulatory functions. Local injection of GMSCs is the superior mode for therapeutic application. PGE2–EP3 signaling plays an important role in the immunomodulatory functions of GMSCs in murine CHS.
Mesenchymal stem cells (MSCs), or mesenchymal stroma cells, are adult progenitor cells present primarily in bone marrow and probably in most adult tissues. MSCs, including human bone marrow-derived MSCs (BMSCs) and adipose-derived stem cells (ASCs), have been shown to possess potent immunomodulatory and anti-inflammatory functions by inhibiting the proliferation and activation of multiple types of innate and adaptive immune cells or promoting the differentiation of regulatory T cells (Tregs) [1–4]. This manifests as decreased production of proinflammatory cytokines and upregulation of growth factors and soluble factors with anti-inflammatory functions [5, 6]. Human gingiva-derived MSCs (GMSCs) were first isolated and identified by Zhang et al. in 2009  and are considered a new source of MSCs with a promising future in regenerative medicine [8, 9]. Recent studies reported that human GMSCs have immunomodulatory properties similar to those of BMSCs, including inhibition of T-cell proliferation and activation, enhancement of Treg generation, and polarization of M2 macrophages [7, 8, 10]. Specifically, GMSCs can be isolated and obtained readily, maintain a normal karyotype and telomerase activity over long-term culture, display a stable phenotype, and proliferate rapidly in vitro [11, 12]. These characteristics render GMSCs a potential novel immunotherapeutic agent. Recently, BMSCs [5, 13, 14] and ASCs [13–15] have been used for the treatment of a variety of immune-related and inflammation-related diseases. However, the different effects between treatments using GMSCs and other types of MSCs have not yet been explored, which might limit their application. This study therefore first compared the immunomodulatory capabilities of BMSCs, ASCs, and GMSCs.
Murine contact hypersensitivity (CHS) is widely used as a model for allergic contact dermatitis (ACD). One of the most common diseases caused by repeated skin exposure to contact allergens, ACD is classified as a type IV or a delayed type hypersensitivity reaction. The CHS model comprises two phases: the sensitization phase, in which skin dendritic cells take up antigens, migrate to regional draining lymph nodes, and stimulate the activation and differentiation of allergen-specific T cells; and the elicitation phase, in which effector T cells evoke immune inflammation upon exposure to antigens . The first-line treatment for ACD is topical application of corticosteroids , which only partially alleviate the local symptoms. There is thus an urgent need for a more effective therapeutic tool. Su et al.  demonstrated that intravenous injection of GMSCs attenuates the appearance of CHS in mice before antigen sensitization and challenge. This suggests that GMSCs administered prophylactically could home to, and function at, the site of local inflammation in tissue. However, GMSC administration after challenge was less effective for CHS attenuation compared with before antigen sensitization and challenge. Thus, evidence is lacking for the efficacy of therapeutic administration of GMSCs. This study therefore focused on the therapeutic administration of GMSCs, particularly on how to increase the efficacy of therapeutic administration.
Although convincing findings for the therapeutic effects of MSCs on a variety of immune-related and inflammation-related diseases have been reported, how to deliver MSCs to targeted sites of inflammation in a timely fashion and in sufficient numbers to optimize their therapeutic effect has attracted increasing levels of attention. Rather than intravenous MSC administration, local MSC administration may be preferable. Multiple studies have demonstrated that topical or subcutaneous application of MSCs to cutaneous wounds promotes their repair in both mice [18–20] and humans [18, 21]. Substantial research has also focused on treatment with locally applied MSCs for complications of diabetes, including polyneuropathy (MSC intramuscular injection) , ischemic hind limb (MSC intramuscular injection) , foot ulcerations (MSC subcutaneous injection) , and diabetic wounds (MSC subcutaneous injection) . Against this background, to explore the therapeutic effects of novel strategies of MSC application in mice with CHS, we compared local and intravenous GMSC administration in our study.
Prostaglandin E2 (PGE2) is metabolized from arachidonic acid by sequential catalysis of COX . PGE2 functions in allergic inflammation by interacting with PGE receptors which are a family of four subtypes of G protein-coupled proteins (EP1, EP2, EP3, and EP4). For example, PGE2 promotes an inflammatory response through Th1 and Th17 cell expansion via EP4 or EP1 signaling [26, 27]; however, PGE2 suppresses skin allergic inflammation via EP3 [16, 28], which is expressed abundantly in the skin . To clarify the role of EP signaling in allergic skin inflammation, this study focused on the interaction between GMSCs and the PGE2–EP pathway in a CHS model.
Nonsteroidal anti-inflammatory drugs (NSAIDs) that block COX would be expected to suppress allergic inflammation in the skin. However, NSAIDs usually have no significant effect on inflammation in CHS in experimental animals or clinical patients, which is attributed to increased levels of leukotriene B4 .
Our research aims to optimize MSC therapy in mice with CHS. First, to identify the preferable MSC type we compared the immunomodulatory functions of isolated GMSCs with the most commonly used MSCs (BMSCs and ASCs) in a CHS model. Second, to optimize the administration methods of MSCs, we explored novel strategies of MSC application, specifically local injection. Last, we investigated the possible mechanisms of the immunomodulatory functions of MSCs, especially the relationship to the PGE2–EP pathway.
GMSCs , ASCs , and BMSCs  were isolated following established protocols (Additional file 1) approved by the Institutional Review Board of Peking University School and Hospital of Stomatology (PKUSSIRB-201311108). Clinically healthy gingiva was collected from routine dental procedures as a remnant or discarded tissue. Alveolar bone marrow was aspirated from patients undergoing routine dental implant placement at Peking University School and Hospital of Stomatology. Human adipose tissues were obtained from healthy patients who underwent liposuction surgery for aesthetic reasons at Peking University Third Hospital, following approved guidelines set by the Health Science Center, Peking University. Human tissue samples were obtained after informed consent from all of the donors.
Cells obtained from the second to sixth passages were used in the experiments. GMSCs were pretreated with 5 M indomethacin (Sigma, St. Louis, MO, USA) in vitro for 24 h and then used for the animal experiments.
MSCs were defined by differentiation into osteogenic, adipogenic, and chondrogenic phenotypes  and expression of the MSC markers CD73, CD105, CD146, STRO1, and CD34, as determined by flow cytometry.
Animal experiments in this study were approved by the laboratory animal welfare ethics branch of the Institutional Review Board of Peking University (LA2015052). BALB/c mice (male, 8–10 weeks old) were obtained from Vital River Laboratories (Beijing, China) and housed in groups in the animal facility of Peking University (Beijing, China). All animal care and experiments were performed using institutional protocols approved by the Institutional Review Board of Peking University School and Hospital of Stomatology.
Our mouse CHS model is similar to that described in previous studies . Initially, 25 μl of 2 % oxazolone in acetone:olive oil (4:1) was applied to the right ear. The ears were then challenged with 15 μl of 2 % oxazolone 7 days after the first sensitization. An equivalent amount of vehicle (acetone:olive oil (4:1)) was administered to the left ear as a control. Ear thickness was measured 5 mm away from the ear margin before and 24 h after the challenge in a blinded fashion, and the difference was used as a parameter of ear swelling.
Initially, five groups of mice (n = 10 per group) were used to compare the treatment effect of GMSCs, BMSCs, ASCs, and corticosteroid. Different types of MSCs (2 × 106 cells per mouse) were applied by intravenous injection (injected into the tail vein) 1 day before sensitization. Skin-derived fibroblasts were injected by the same method as the CHS control. Approximately 30 mg of 0.025 % triamcinolone acetonide acetate cream (Qiangsheng, Beijing, China), a commonly used corticosteroid, was topically applied 2 h after challenge and then at 12-h intervals as a treatment control for each ear.
Next, GMSCs (2 × 106 cells per mouse) were applied by two methods, intravenous or local injection (see Additional file 2), at three time points: 1 day before sensitization, 1 day before initiation or challenge, and 1 h after challenge (n = 10 mice for each method at each time point). For local injection, we chose three injection points on the bottom skin of the ears. The distance from the injection site to the ear margins was >3 mm. Skin-derived fibroblasts (2 × 106) were injected by the same method as the CHS control.
We also applied 16,16-dimethyl-PGE2 at four different dosages (5, 10, 15, and 20 μg/kg) subcutaneously into CHS mice 1 h after challenge (n = 5 mice for each dosage). GMSCs were pretreated with 5 μM indomethacin in vitro to block PGE2 release completely and referred to as indomethacin-pretreated GMSCs (IGMSCs). Then 2 × 106 skin-derived fibroblasts, GMSCs, IGMSCs, IGMSCs + PGE2, and sulprostone (0.1 mg/kg; Cayman Chemical, Ann Arbor, MI, USA) were subcutaneously applied to five groups of mice (n = 5 mice per group) 1 h after challenge.
Mice were sacrificed on day 2 after challenge, and ear samples were harvested for further analysis.
Hematoxylin and eosin staining was performed on paraffin wax-embedded sections for histological examination. Immunohistochemical staining of collagen type II was performed using an antibody specific to human FceRIa. Immunohistochemical staining was performed using antibodies specific for mouse CD11b and human leukocyte antigen (HLA) (Abcam, Cambridge, UK) in paraffin sections of ears. Isotype-matched control antibodies (eBiosciences, San Diego, CA, USA) were used as negative controls.
Enzyme-linked immunosorbent assay and western blot analysis
Cytokine concentrations in serum were assessed using enzyme-linked immunosorbent assay (ELISA) kits (eBioscience), and data were normalized by protein concentration. Western blot analysis of ear tissue was performed using antibodies specific to mouse tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), IL-4, interferon-gamma (IFN-γ), IL-10, nuclear factor-kappa B (NF-kB), p65, Foxp3, CD4, transforming growth factor beta (TGF-β), inducible nitric oxide synthase (iNOS), EP1, EP2, EP3, EP4, and β-actin (Abcam).
Data were collected from at least three independent experiments and analyzed using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA) and GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, CA, USA). After testing the normality of the data and confirming the applicability of these tests, one-way analysis of variance (ANOVA) was used to compare the means of multiple groups and Student’s t test was used to compare the means between two groups (e.g., intravenous vs local injection). Differences between groups were considered statistically significant at p < 0.05. Power analysis with NCSS-PASS (version 11.0; NCSS, Kaysville, UT, USA) was performed to ascertain whether the sample size was sufficient within the allowable error rate (α = 0.05, 1 – β = 0.9) after obtaining the data. The sample size of our research provides over 85 % power to detect differences among the means versus the alternative of equal means using an F test with a 0.05 significance level, which verifies the significance of our results.
Therapeutic effects of various MSC administration methods
Therapeutic effects of intravenous and local injection of GMSCs 1 h after challenge
GMSCs attenuate CHS via PGE2–EP3 signaling
Western blot showed increased production of EP3 and reduced production of EP1, EP2, and EP4 in local GMSC-treated inflammatory tissue (Fig. 9d). To determine which PGE2 receptor mediated the GMSC-mediated immunosuppression of CHS, sulprostone, an agonist of EP3, was subcutaneously applied 1 h after challenge and resulted in significant suppression of CHS (Fig. 9e). In addition, the simultaneous application of sulprostone and IGMSCs significantly suppressed CHS appearance, similar to the simultaneous application of PGE2 and IGMSCs (see Additional file 4). Taken together, these findings indicated that EP3 was associated with the immunomodulatory functions of GMSCs.
The gingiva serves as a mucosal barrier to protect the oral cavity side of the maxilla and mandible; however, it also has some unique features. For example, wound healing within the gingiva and oral mucosa is characterized by markedly reduced inflammation, rapid re-epithelialization, and fetal-like scarless healing, in stark contrast to the common scar formation present in skin . The gingiva might thus also have an immune profile associated more with mucous membranes than with bone marrow or adipose tissue, and therefore GMSCs may exhibit differences in immunological response compared with bone marrow or adipose mesenchymal stromal cells. GMSCs as a novel type of MSCs express lower MSC-related markers than BMSCs and ASCs (flow cytometry of ASCs see Additional file 5), which is consistent with previous reports [10, 11, 33]. MSCs possess potent immunomodulatory functions both in vitro and in vivo . Recent research suggests that GMSCs exert similar immunosuppressive effects in vitro and in vivo [8, 10, 11, 35]. Here, we found that application of GMSCs, ASCs, and BMSCs suppressed the symptoms of CHS more effectively compared with the application of 0.025 % triamcinolone acetonide acetate, and that GMSC administration exhibited the greatest treatment efficacy. Topical corticosteroids, as a standard therapy for CHS, did not achieve the expected results. Because the therapeutic effect of topical corticosteroids is related to the type, concentration, and dosage of drug, the method and the probably insufficient dosage we used may contribute to this insufficient effect. Topical corticosteroid treatment is therefore an inadequate positive control for CHS treatment.
The enhanced treatment effect in CHS and the lower expression of MSC-related markers of GMSCs might be associated with their unique developmental source. A previous study  showed that, apart from 10 % of GMSCs from the mesoderm, 90 % of GMSCs are derived from cranial neural crest cells, and show an elevated capacity to induce activated T-cell apoptosis in vitro and upregulation of the expression FAS ligand (FASL), a transmembrane protein that plays an important role in MSC-based immunomodulation . In addition, in mice with dextran sulfate sodium (DSS)-induced experimental colitis, GMSCs derived from cranial neural crest cells resulted in better therapeutic effects with regards to body weight loss, diarrhea, bleeding, histological recovery of the epithelial structure, and the numbers of inflammatory cells, Tregs, and Th17 cells compared with those from mesoderm. This may result in the difference between GMSCs and other types of MSCs. Several comparative studies on the immunomodulatory functions of ASCs and BMSCs have been published [13, 36, 37]; however, the present study is the first to compare the immunomodulatory efficacy of GMSCs, ASCs, and BMSCs in vivo. Our findings suggest that GMSCs are an effective immunotherapeutic tool due to their more powerful immunomodulatory effect and accessibility, which might have important implications in clinical practice. However, there are few related reports in the literature, and the underlying mechanism of the powerful immunomodulatory function of GMSCs remains largely unknown; further studies are therefore needed.
Regarding the administration time of GMSCs in the treatment of CHS, Su et al.  showed that prophylactic administration of GMSCs (intervention before sensitization) exhibited greater efficacy. However, while prophylactic administration of GMSCs might benefit some patients with chronic ACD, therapeutic administration of GMSCs is needed more urgently and may have more significant clinical importance. In contrast, although MSCs have been intravenously applied to treat a variety of immune-related and inflammation-related diseases in many clinical trials, how MSCs target specific tissues is largely unknown. This may be why clinical dosing currently includes high numbers of cells . Despite the systemic immunoregulatory function of intravenously infused MSCs, the cells migrate through the circulatory system and finally home in on target sites. The risk of being taken out of circulation and the long distance to target sites may delay or prevent their local function at such sites . Greater consideration of direct MSC administration is therefore needed to target sites where MSCs are located immediately, avoiding passage through the vascular system and the release of bioactive factors acting on surrounding tissue. However, for most target sites, it is usually difficult to apply MSCs directly. An exception to this is the skin, which is superficial and has a large surface area for direct MSC administration. In research comparing the efficacy between systemic and local MSC therapy for diabetic wound healing, local MSC therapy achieved a better effect . Therefore, to enhance the treatment effect of therapeutic administration of GMSCs to CHS, we compared the effects of local injection with those of intravenous injection. We found that local administration exerted a positive effect when intervention was performed later in the course of the disease. Local infusion is therefore the superior option for therapeutic administration of GMSCs. Locally injected GMSCs can function in a more effective manner. To date this is the first exploratory work to focus on the function and effect of locally applied GMSCs, and it might have profound implications in clinical practice. Further studies should address the practical feasibility of local application of MSC-based therapy for the prevention and treatment of allergic diseases, including allergic rhinitis  and asthma , because even intravenous administration of MSCs before sensitization also exerts significant ameliorative effects in mouse models.
CHS is categorized as a type IV or a delayed type hypersensitivity reaction, which involves a wide range of innate and adaptive immune cells and inflammatory cytokines [41, 42]. In our study, GMSC administration resulted in a significant reduction in inflammatory cell infiltration and the levels of various proinflammatory cytokines in local allergic areas, which suggest that GMSCs may target multiple types of innate and adaptive immune cells. At the same time, GMSCs inhibited inflammation by promoting the induction and functions of Tregs, as evidenced by increased production of Foxp3, IL-10, and TGF-β. These results are consistent with reports that described the role of Tregs in preventing the development of allergic reactions and limiting the magnitude of the inflammatory process [43, 44]. However, the difference in the circulating and local levels of inflammatory cytokines may be related to the difference in test time and the reduced absorption of GMSCs into the circulation after local injection. Moreover, GMSCs promoted the reconstitution of the disrupted Th1/Th2 balance, as determined by the decreased IFN-γ/IL-4 ratio. This result provides evidence for the capacity of GMSCs to induce immunologic reactions to restore homeostasis. The reduction of inflammatory cytokines and the modified Th1/Th2 balance in murine serum provide evidence that locally applied MSCs have a systemic immunoregulatory function, which conflicts with research in which intramuscular MSC injection was applied to treat rats with diabetic polyneuropathy . This previous study found that MSCs remained at the transplant sites without having any systemic effects. Therefore, further studies are warranted to dissect the detailed mechanisms by which locally and intravenously applied GMSCs affect the complex interactions among these immune cells during the course of CHS.
iNOS is a messenger molecule with diverse functions throughout the body. It has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such as COX2 . In fact, it has been revealed that MSC-mediated immunosuppression varies among different mammalian species; IDO mediates immunosuppression by human MSCs, while iNOS plays a similar role in mouse MSCs . Our study indicated that the immunomodulatory functions of GMSCs may be associated with the decreased expression of iNOS in mice with CHS. However, the exact mechanism by which MSCs act on iNOS requires further research.
We did not detect systemically infused GMSCs in locally sensitized ears at 24 and 48 h after challenge. Systemically infused MSCs risk being taken out of circulation, on either a temporary or a permanent basis, in organs such as the lungs, spleen, and liver . Upon reaching target sites, MSCs must exit the vasculature to enter the connective tissue stromal region where their principal functions occur . There is ample evidence of systemically infused MSC homing in on local organs, especially the bone marrow, lungs, spleen, and liver . With regards to the skin, systemically infused GMSCs were detected in healing wounds 7 days after cell injection in mice with cutaneous wounds . A report has also described that GMSCs were detected in mucosa 5 days after intravenous injection in mice with chemotherapy-induced oral mucositis . Thus, we infer that, in our study, few homing cells may have been associated with the examined time period. In addition, the heterogeneous source of cells may accelerate MSC deletion. Therefore, we speculate that intravenously applied GMSCs play an anti-inflammatory role through systemic immunomodulation. Subcutaneously applied GMSCs were detected at 24 and 48 h, which provides evidence that locally applied MSCs can migrate to surrounding tissues and function there in a more efficient manner. The difference in the number of GMSCs between 24 and 48 h may be related to the examined position of the ears.
Despite heterogeneous GMSCs being used in this study, no obvious symptoms of xenorejection were observed in the treated mice. In fact, some studies have reported the administration of human MSCs in mouse disease models without immunosuppression. For example, Stoff et al.  injected concentrated human MSCs into sites adjacent to incisional wounds made in the skin of rabbits, which resulted in enhanced wound healing. The rabbits used in that study were fully immunocompetent, and no immunosuppressive drugs were given. Moreover, human GMSCs were intravenously injected to treat CHS  and experimental colitis  in mice (C57BL/6 mice) without the application of immunosuppressive drugs, which produced good results. In addition, research reported that MSCs might increase tolerance for the engraftment of skin equivalents constructed from allogeneic cells and help to promote vascular ingrowth into the graft [49–51]. Notably, no evidence has been reported for the rejection of injected xenogeneic human MSCs . Possible reasons for this include the low immunogenicity and immunomodulatory functions of MSCs.
Generally, PGE2 is considered an inflammatory mediator, but it plays a complex role in the development of allergic reactions. Our study reveals that the reduced level of GMSC-derived PGE2 induced by indomethacin (an inhibitor of cyclooxygenase) reversed the majority of the inhibition of CHS by GMSCs. These results indicate that PGE2 is necessary for GMSC-induced immunomodulation and GMSCs may suppress inflammatory reactions by autocrine PGE2. The combined application of PGE2 and IGMSCs partially reversed the effect of indomethacin pretreatment. The dose-dependent suppression of CHS by low-dose PGE2 administration indicates that endogenous PGE2 acts in situ in the skin to modulate the extent of CHS-induced inflammation. All of these findings indicate that PGE2 is one of the most important factors mediating the immunomodulatory functions of GMSCs. The therapeutic effects of PGE2 on skin allergic inflammation are dependent on its interactions with the various receptor subtypes. In the present study, GMSC administration inhibited the expression of EP1, EP2, and EP4 and promoted that of EP3. Sulprostone is an agonist of EP3 and EP1, with considerably greater affinity for EP3 than for EP1 (Ki = 0.6 and Ki = 21, respectively) , and sulprostone application led to significant suppression of CHS, similar to GMSC application. These findings suggest that stimulation of EP3 with an exogenously added agonist can control allergic inflammation in the skin. PGE2–EP3 signaling plays an important role in the immunomodulatory functions of GMSCs in murine CHS. However, the molecular mechanisms underlying the immunomodulatory effect of PGE2–EP3 signaling require further research.
Like COX, arachidonic acid is also metabolized by lipoxygenase. As mentioned, NSAIDs adversely affect the diversion from arachidonate metabolism to the lipoxygenase pathway, leading to an increase in leukotriene B4. However, our study suggests another explanation for the adverse effects of NSAIDs in inflammatory skin diseases: NSAIDs weaken the anti-inflammatory effects of PGE2–EP3 signaling.
In summary, this study showed, for the first time, that PGE2–EP3 signaling plays an important role in the immunomodulatory functions of GMSCs in murine CHS. In addition, local infusion, which led to more marked attenuation of CHS during the late phase of disease, is the superior option for therapeutic administration of GMSCs. Furthermore, compared with other types of MSCs, more powerful immunomodulatory functions and accessibility render GMSCs a preferable novel immunotherapeutic.
ACD, allergic contact dermatitis; ASC, adipose-derived stem cell; BMSC, bone marrow-derived mesenchymal stem cell; CHS, contact hypersensitivity; GMSC, gingiva-derived mesenchymal stromal cell; IGMSC, indomethacin-pretreated mesenchymal stem cell; MSC, mesenchymal stem cell; NSAID, nonsteroidal anti-inflammatory drug; PGE2, prostaglandin E2; Treg, regulatory T cell
This work was supported by grants from the National Natural Science Foundation of China (no.81170928) and the 985 project of Peking University (no.20130401).
LG conceived and designed the experiments, and checked and revised the whole manuscript. PL performed the experiments, analyzed the data, and wrote the manuscript. YZ analyzed the data, and checked and revised the whole manuscript. All authors read and approved the manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kimbrel EA, Kouris NA, Yavanian GJ, Chu J, Qin Y, Chan A, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 2014;23(14):1611–24. doi:10.1089/scd.2013.0554.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng PP, Liu XC, Ma PF, Gao C, Li JL, Lin YY, et al. iPSC-MSCs combined with low-dose rapamycin induced islet allograft tolerance through suppressing Th1 and enhancing regulatory T-cell differentiation. Stem Cells Dev. 2015;24(15):1793–804. doi:10.1089/scd.2014.0488.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015;24(1):93–103. doi:10.1089/scd.2014.0155.View ArticlePubMedGoogle Scholar
- Benvenuto F, Voci A, Carminati E, Gualandi F, Mancardi G, Uccelli A, et al. Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. Stem Cell Res Ther. 2015;6(1):245. doi:10.1186/s13287-015-0222-y.View ArticlePubMedPubMed CentralGoogle Scholar
- English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell. 2010;7(4):431–42. doi:10.1016/j.stem.2010.09.009.View ArticlePubMedGoogle Scholar
- Tolar J, Le Blanc K, Keating A, Blazar BR. Concise Review: Hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010;28(8):1446–55. doi:10.1002/stem.459.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol. 2009;183(12):7787–98.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang QZ, Su WR, Shi SH, Wilder-Smith P, Xiang AP, Wong A, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28(10):1856–68. doi:10.1002/stem.503.View ArticlePubMedPubMed CentralGoogle Scholar
- Diniz IM, Chen C, Ansari S, Zadeh HH, Moshaverinia M, Chee D, et al. Gingival mesenchymal stem cell (GMSC) delivery system based on RGD-coupled alginate hydrogel with antimicrobial properties: a novel treatment modality for peri-implantitis. J Prosthodont. 2016;25(2):105–15. doi:10.1111/jopr.12316.View ArticlePubMedGoogle Scholar
- Zhang Q, Nguyen AL, Shi S, Hill C, Wilder-Smith P, Krasieva TB, et al. Three-dimensional spheroid culture of human gingiva-derived mesenchymal stem cells enhances mitigation of chemotherapy-induced oral mucositis. Stem Cells Dev. 2012;21(6):937–47. doi:10.1089/scd.2011.0252.View ArticlePubMedGoogle Scholar
- Zhao N, Wu Z, Qin L, Guo Z, Li D. Characteristics and tissue regeneration properties of gingiva-derived mesenchymal stem cells. Crit Rev Eukaryot Gene Expr. 2015;25(2):135–44.View ArticlePubMedGoogle Scholar
- Wu SM, Chiu HC, Chin YT, Lin HY, Chiang CY, Tu HP, et al. Effects of enamel matrix derivative on the proliferation and osteogenic differentiation of human gingival mesenchymal stem cells. Stem Cell Res Ther. 2014;5(2):52. doi:10.1186/scrt441.View ArticlePubMedPubMed CentralGoogle Scholar
- Stavely R, Robinson AM, Miller S, Boyd R, Sakkal S, Nurgali K. Human adult stem cells derived from adipose tissue and bone marrow attenuate enteric neuropathy in the guinea-pig model of acute colitis. Stem Cell Res Ther. 2015;6(1):244. doi:10.1186/s13287-015-0231-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res. 2010;316(19):3109–23. doi:10.1016/j.yexcr.2010.08.008.View ArticlePubMedGoogle Scholar
- Cho K-S, Park H-K, Park H-Y, Jung JS, Jeon S-G, Kim Y-K, et al. IFATS Collection: Immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells. 2009;27(1):259–65. doi:10.1634/stemcells.2008-0283.View ArticlePubMedGoogle Scholar
- Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E2–EP3 signaling suppresses skin inflammation in murine contact hypersensitivity. J Allergy Clin Immunol. 2009;124(4):809–18.e2. doi:10.1016/j.jaci.2009.04.029.
- Su WR, Zhang QZ, Shi SH, Nguyen AL, Le AD. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells. 2011;29(11):1849–60. doi:10.1002/stem.738.View ArticlePubMedGoogle Scholar
- Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng. 2007;13(6):1299–312. doi:10.1089/ten.2006.0278.View ArticlePubMedGoogle Scholar
- McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, et al. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen. 2006;14(4):471–8. doi:10.1111/j.1743-6109.2006.00153.x.View ArticlePubMedGoogle Scholar
- Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25(10):2648–59. doi:10.1634/stemcells.2007-0226.View ArticlePubMedGoogle Scholar
- Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol. 2003;139(4):510–6. doi:10.1001/archderm.139.4.510.View ArticlePubMedGoogle Scholar
- Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57(11):3099–107. doi:10.2337/db08-0031.View ArticlePubMedPubMed CentralGoogle Scholar
- Hirata K, Li TS, Nishida M, Ito H, Matsuzaki M, Kasaoka S, et al. Autologous bone marrow cell implantation as therapeutic angiogenesis for ischemic hindlimb in diabetic rat model. Am J Physiol Heart Circ Physiol. 2003;284(1):H66–70. doi:10.1152/ajpheart.00547.2002.View ArticlePubMedGoogle Scholar
- Vojtassak J, Danisovic L, Kubes M, Bakos D, Jarabek L, Ulicna M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett. 2006;27 Suppl 2:134–7.PubMedGoogle Scholar
- Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008;5(3):453–63. doi:10.1111/j.1742-481X.2007.00408.x.View ArticlePubMedGoogle Scholar
- Nagamachi M, Sakata D, Kabashima K, Furuyashiki T, Murata T, Segi-Nishida E, et al. Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. J Exp Med. 2007;204(12):2865–74. doi:10.1084/jem.20070773.View ArticlePubMedPubMed CentralGoogle Scholar
- Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E-2-EP4 signaling promotes immune inflammation through T(H)1 cell differentiation and T(H)17 cell expansion. Nat Med. 2009;15(6):633–U141. doi:10.1038/nm.1968.View ArticlePubMedGoogle Scholar
- Kunikata T, Yamane H, Matsuoka T, Tanaka H, Nagai H, Narumiya S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. J Pharmacol Sci. 2006;100:95.Google Scholar
- Tober KL, Thomas-Ahner JM, Kusewitt DF, Oberyszyn TM. Effects of UVB on E prostanoid receptor expression in murine skin. J Invest Dermatol. 2007;127(1):214–21. doi:10.1038/sj.jid.5700502.View ArticlePubMedGoogle Scholar
- Liu Y, Zhou Y, Feng H, Ma GE, Ni Y. Injectable tissue-engineered bone composed of human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2008;29(23):3338–45. doi:10.1016/j.biomaterials.2008.04.037.View ArticlePubMedGoogle Scholar
- Zhang W, Zhang X, Wang S, Xu L, Zhang M, Wang G, et al. Comparison of the use of adipose tissue-derived and bone marrow-derived stem cells for rapid bone regeneration. J Dent Res. 2013;92(12):1136–41. doi:10.1177/0022034513507581.View ArticlePubMedGoogle Scholar
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.View ArticlePubMedGoogle Scholar
- Xu X, Chen C, Akiyama K, Chai Y, Le AD, Wang Z, et al. Gingivae contain neural-crest- and mesoderm-derived mesenchymal stem cells. J Dent Res. 2013;92(9):825–32. doi:10.1177/0022034513497961.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang J, Huang X, Wang H, Liu X, Zhang T, Wang Y, et al. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther. 2015;6:234. doi:10.1186/s13287-015-0240-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Linard C, Tissedre F, Busson E, Holler V, Leclerc T, Strup-Perrot C, et al. Therapeutic potential of gingival fibroblasts for cutaneous radiation syndrome: comparison to bone marrow-mesenchymal stem cell grafts. Stem Cells Dev. 2015;24(10):1182–93. doi:10.1089/scd.2014.0486.View ArticlePubMedPubMed CentralGoogle Scholar
- Elman JS, Li M, Wang F, Gimble JM, Parekkadan B. A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm. 2014;11(1):1. doi:10.1186/1476-9255-11-1.View ArticleGoogle Scholar
- Semon JA, Maness C, Zhang X, Sharkey SA, Beuttler MM, Shah FS, et al. Comparison of human adult stem cells from adipose tissue and bone marrow in the treatment of experimental autoimmune encephalomyelitis. Stem Cell Res Ther. 2014;5(1):2. doi:10.1186/scrt391.View ArticlePubMedPubMed CentralGoogle Scholar
- Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206–16. doi:10.1016/j.stem.2009.02.001.View ArticlePubMedGoogle Scholar
- Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. Stem Cell Res Ther. 2010;1(4):30. doi:10.1186/scrt30.View ArticlePubMedPubMed CentralGoogle Scholar
- Goodwin M, Sueblinvong V, Eisenhauer P, Ziats NP, LeClair L, Poynter ME, et al. Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells. 2011;29(7):1137–48. doi:10.1002/stem.656.View ArticlePubMedPubMed CentralGoogle Scholar
- Fonacier LS, Dreskin SC, Leung DYM. Allergic skin diseases. J Allergy Clin Immunol. 2010;125(2):S138–49. doi:10.1016/j.jaci.2009.05.039.View ArticlePubMedGoogle Scholar
- Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1699–714. doi:10.1111/j.1398-9995.2009.02082.x.View ArticlePubMedGoogle Scholar
- Ring S, Karakhanova S, Johnson T, Enk AH, Mahnke K. Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol. 2010;125(1):237–46. doi:10.1016/j.jaci.2009.10.025.View ArticlePubMedGoogle Scholar
- Ring S, Oliver SJ, Cronstein BN, Enk AH, Mahnke K. CD4(+)CD25(+) regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol. 2009;123(6):1287–96. doi:10.1016/j.jaci.2009.03.022.View ArticlePubMedGoogle Scholar
- Seppala O, Karvonen A, Valtonen ET, Jokela J. Interactions among co-infecting parasite species: a mechanism maintaining genetic variation in parasites? Proc Biol Sci. 2009;276(1657):691–7. doi:10.1098/rspb.2008.1229.View ArticlePubMedGoogle Scholar
- Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X, et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res. 2014;74(5):1576–87. doi:10.1158/0008-5472.can-13-1656.View ArticlePubMedPubMed CentralGoogle Scholar
- De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells. 2016;8(3):73–87. doi:10.4252/wjsc.v8.i3.73.View ArticlePubMedPubMed CentralGoogle Scholar
- Stoff A, Rivera AA, Sanjib Banerjee N, Moore ST, Michael Numnum T, Espinosa-de-Los-Monteros A, et al. Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol. 2009;18(4):362–9. doi:10.1111/j.1600-0625.2008.00792.x.View ArticlePubMedGoogle Scholar
- Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42–8.View ArticlePubMedGoogle Scholar
- Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R, et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant. 2006;15(8-9):711–21.View ArticlePubMedGoogle Scholar
- Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1(1):2. doi:10.1186/scrt2.View ArticlePubMedPubMed CentralGoogle Scholar
- Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193–226.PubMedGoogle Scholar